Halozyme’s ENHANZE is a recombinant human hyaluronidase PH20 enzyme (rHuPH20) for quick subcutaneous drug delivery. Acumen plans to evaluate the potential application of this technology in the development
Krazati has been approved as a monotherapy to treat adult patients with advanced NSCLC with KRASG12C mutation and who have progressive disease after previous therapy with, or intolerance
This acquisition will expand the range of services available to Noramco and its subsidiary Purisys’ active pharmaceutical ingredients (API) customers. The services include drug product formulation development, clinical
Under the multi-year, multi-programme collaboration, the companies will discover, develop, and commercialise therapies for cancer patients. Prelude’s capabilities in medicinal chemistry, targeted protein degradation and clinical development will
The newly expanded, 8,000ft2 space has a test material department. It features advanced equipment and 48 workbenches, with a wide range of services, including flow cytometry, ligand binding
Next year, Basilea will explore multiple hypotheses through preclinical studies to identify the optimal future clinical development programme for tonabacase. Under an exclusive option, Basilea will license tonabacase
The deal will be effected by way of a three-cornered amalgamation between SecureDose, Pharmadrug and its wholly owned subsidiary. As per the terms of this transaction, all the
Designed to serve as an incubator facility, the new modern facility includes ISO 7 cGMP cleanroom suites, as well as research and development (R&D) labs. The ReadyStart cGMP
Donesta is Mithra’s investigational next-generation medicine, which contains Estetrol, to treat menopause symptoms. In July this year, Mithra and Searchlight signed a binding term sheet for a licensing
Under the deal, Moderna will utilise Caris’ library of de-identified, multi-modal data solutions generated from whole exome sequencing, whole transcriptome sequencing, and protein analyses, in addition to claims
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.